RecruitingNot ApplicableNCT06820190

Analgesic Efficacy of Multiple Mid-Transverse Process to Pleura (MTP) Block and PCA in Idiopathic Scoliosis Patients Undergoing Posterior Spinal Fusion

Comparison of Analgesic Efficacy of Multiple Mid-Transverse Process to Pleura (MTP) Block and PCA in Idiopathic Scoliosis Patients Undergoing Posterior Spinal Fusion: A Randomized Clinical Trial


Sponsor

Tanta University

Enrollment

40 participants

Start Date

Feb 12, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

This study aims to compare the analgesic efficacy of multiple mid-transverse process to pleura (MTP) block and PCA in idiopathic scoliosis patients undergoing posterior spinal fusion surgery.


Eligibility

Min Age: 18 Years

Inclusion Criteria4

  • Age ≥ 18 years.
  • Both sexes.
  • American Society of Anesthesiology (ASA) physical status I-II.
  • Idiopathic scoliosis patients undergoing posterior spinal fusion surgery.

Exclusion Criteria8

  • Patients with pre-existing infection at block site.
  • Known allergy to study drugs.
  • Coagulation disorder.
  • History of psychiatric illness.
  • Pre-existing neurological deficits.
  • Patient with morbid obesity (body mass index \>40 kg/m2).
  • Presence of any pre-operative pain or history of chronic pain.
  • History of regular analgesic.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERMultiple Mid-Transverse Process to Pleura (MTP) Block

Patients will receive multiple mid-transverse process to pleura (MTP) block after induction of anesthesia.

DRUGMorphine

Patients will receive IV-PCA. Morphine is generally administered as an initial loading dose of 0.05-0.1 mg/kg before the end of surgery, with PCA settings of a bolus dose of 0.01-0.03 mg/kg, a lockout interval of 6-10 min, and a background infusion of 0.01-0.02 mg/kg/h.


Locations(1)

Tanta University

Tanta, El-Gharbia, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06820190


Related Trials